Morning Briefing
Summaries of health policy coverage from major news organizations
Perspectives: What Is Behind The ADHD Medication Shortage?
The New York Times: The A.D.H.D. Drug Shortage Is Causing Real Pain
Today, a nationwide shortage of the A.D.H.D. medications he relies on threatens his recovery. This drought of drugs like Adderall, Vyvanse and Ritalin — which has now stretched on for a year — is causing widespread suffering and increasing levels of disability among families across the United States. (Maia Szalavitz, 10/9)
The New York Times: Ozempic Can’t Fix What Our Culture Has Broken
We have become fluent in the new language of pharmacology, diabetes, and weight loss. Ozempic, Wegovy and Mounjaro are part of our public lexicon. Glucagon-like peptide-1 (GLP-1) receptor agonists are lifesaving drugs, created to help the hundreds of millions of people with Type 2 diabetes and clinical obesity. They promise to rid the United States of obesity, if our country can figure out how to make the pricey fix affordable. (Tressie McMillan Cottom, 10/9)
Stat: Payer-Participating Trials Could Improve Drug Efficacy
Earlier this year, Food and Drug Administration Commissioner Robert M. Califf proposed something radical: that private health care insurance companies (payers) should participate in clinical research on FDA-approved drugs. (Vijay Ramakrishnan, 10/6)
